Lifelong impacts of puberty timing on human plasma metabolic 1

profiles 2

- Zengjun Li, MB¹; Si Fang, MS^{2, 3}; Dong Liu, MPH⁴; Fei Li^{*}, MD^{4, 5, 6}, Cairong 3
- Zhu*, PhD1; Jian Zhao*, PhD4, 6 4

Affiliations: 5

- 1. Department of Epidemiology and Biostatistics, West China School of Public Health 6
- and West China Fourth Hospital, Sichuan University, 610041, China. 7
- 8 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol,
- 9 United Kingdom.
- 10 3. Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), University
- 11 of Bristol, Bristol, United Kingdom.
- 4. Ministry of Education and Shanghai Key Laboratory of Children's Environmental 12
- 13 Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine,
- 14 Shanghai, 200092, China
- 15 5. Department of Developmental and Behavioral Pediatric & Child Primary Care,
- Brain and Behavioral Research Unit of Shanghai Institute for Pediatric Research, 16
- 17 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,

18 China

- 6. Department of Maternal and Child Health, School of Public Health, Shanghai Jiao 19
- Tong University, 200092, China. 20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 *Corresponding author:

- 22 Dr Jian Zhao, Ministry of Education and Shanghai Key Laboratory of Children's
- 23 Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of
- 24 Medicine, Shanghai, 200092, China (jzhao.epi@gmail.com).
- 25 Dr Cairong Zhu, Department of Epidemiology and Biostatistics, West China School
- of Public Health and West China Fourth Hospital, Sichuan University, 610041, China
- 27 (cairong.zhu@hotmail.com).
- 28 Dr Fei Li, Department of Developmental and Behavioral Pediatric & Child Primary
- 29 Care, Brain and Behavioral Research Unit of Shanghai Institute for Pediatric Research,
- 30 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
- 31 200092, China (feili@shsmu.edu.cn).

33 Abstract

There has been uncertainty regarding the long-term impact of puberty timing on 34 35 human plasma metabolites. This lack of clarity can be attributed to the influence of confounding factors present in conventional observational studies. To determine the 36 37 causal effect of puberty timing on plasma metabolites, we employed a two-sample 38 Mendelian randomization (MR) analysis, complemented by MR mediation analysis assessing the direct effect. We utilized data from a large-scale meta-analysis of 39 genome-wide association studies (GWAS) on puberty timing, consisting of 329,345 40 41 women of European ancestry, and a meta-analysis of GWAS on plasma metabolites, involving up to 86,507 individuals. Our findings provide moderate evidence 42 supporting a causal effect of puberty timing on 23 out of 174 plasma metabolites. 43 After excluding 7 single nucleotide polymorphisms (SNPs) related to birth weight and 44 childhood adiposity, causal effects remained for 16 metabolites. Through two-step 45 46 MR analysis, we observed strong evidence that adulthood adiposity mediated the causal relationships of puberty timing on 35 plasma metabolites. We also observed 47 moderate evidence for an independent causal effect of puberty timing on 10 48 49 metabolites through multivariable MR analysis. We further used metabolomic data measured in the UK Biobank (UKB) to perform a replication analysis to validate the 50 51 causal effect estimated. Nine amino acids were identified in the UKB, and the replication analysis supported our main findings. 52

53 Introduction

The onset of puberty, influenced by a combination of genetic and environmental factors ^{1,2}, plays a pivotal role in shaping growth and development throughout an individual's lifespan ³. Early puberty onset has been associated with various

57	unfavorable health outcomes, including childhood and adulthood obesity ^{4,5} , type 2
58	diabetes ⁶ , hypertension ⁷ , breast cancer ⁸ , and mental disorders ⁹ . The hormonal
59	fluctuations during puberty initiation trigger metabolic changes that can have
60	significant implications ³ . The investigation of the causal relationship between puberty
61	timing and plasma metabolites in adulthood is of utmost importance, given the
62	increasing recognition of plasma metabolites as effective biomarkers for illness
63	diagnosis and prognosis ^{10,11} . This exploration will provide insights into the long-
64	lasting effects of early-life determinants, such as puberty onset, on human metabolism
65	later in life. Unfortunately, previous studies on this subject have been limited,
66	predominantly relying on conventional multivariable analysis methods that are
67	susceptible to confounding or reverse causation biases ^{5,12,13} . Additionally, the
68	utilization of longitudinal studies for the examination of the correlation between
69	puberty timing and the concentration of plasma metabolites necessitates an extended
70	duration of follow-up, resulting in limited empirical support.
71	Mendelian randomization (MR) is an increasingly used study design that employs
72	genetic variants as instrumental variables to draw causal inferences between an
73	exposure of interest (e.g., puberty timing) and an outcome (e.g., a metabolite) ¹⁴ . MR
74	analyses are much less vulnerable to conventional confounding as a result of the
75	random assignment of alleles during meiosis ¹⁵ , hence differentiating MR from normal
76	observational research. Moreover, MR analyses are less prone to reverse causation
77	because the assortment of alleles precedes the initiation of exposure (e.g., puberty
78	timing).

A recent MR study investigated if puberty timing has a distinct influence on adulthood
 cardiometabolic traits ¹⁶. The results suggested that the effects of puberty timing on

81	adulthood adiposity and cardiometabolic traits are not likely driven by itself but by
82	childhood adiposity. Additionally, it is worth noting that the majority of the
83	cardiometabolic characteristics examined in this study mostly focused on lipids,
84	resulting in a very restricted range of metabolites investigated. Consequently, in this
85	study, we aimed to examine whether puberty timing is likely to, directly and/or
86	indirectly, impact a wide range of plasma metabolites, including amino acids,
87	biogenic amines, acylcarnitines, phosphatidylcholines, lysophosphatidylcholines,
88	sphingomyelins, and hexose in adulthood in a two-sample MR framework. Along with
89	conducting univariable MR analysis to infer the total effect of puberty timing on
90	plasma metabolites, we also performed MR mediation analysis to take the mediating
91	effect of adulthood adiposity into account.

92 **Results**

93 Lifelong causal effects of puberty timing on human metabolites

The study design is illustrated in **Fig 1**. In the primary analysis, all genetically 94 95 significant SNPs were used as instrument variables. Additionally, to minimize the bias 96 arising from horizontal pleiotropy, a secondary analysis was also performed by excluding SNPs that were genetically associated with confounders (e.g., birth weight 97 98 and childhood adiposity) (Fig 2). Two-sample MR analysis suggested moderate 99 causal associations between genetically predicted puberty timing and 23 plasma metabolites within the subclasses including acylcarnitines, amino acids, biogenic 100 101 amines, and lysophosphatidylcholines based on the primary analysis (i.e., inverse-102 variance weighted (IVW) analysis) results (Fig 3-4; Table S7) with P values ranging from 9.09×10^{-4} to 4.92×10^{-2} . The MR analysis results supported positive causal 103 104 associations of later puberty timing with higher levels of 20 metabolites. The strongest

105 causal evidence was found for dodecanedioylcarnitine (beta = 0.11, 95% CI: 0.04 to 106 $0.17, P = 9.09 \times 10^{-4}$), which means each year delayed puberty onset was associated 107 with 0.11 standard deviation (SD) units higher of dodecanedioylcarnitine. By contrast, 108 lower levels of three amino acids, aspartate (beta = -0.04, 95% CI: -7.19 × 10⁻² to -

109 6.40×10^{-4} , $P = 4.60 \times 10^{-2}$), phenylalanine (beta = -0.03, 95% CI: -5.03 × 10^{-2} to -

110 1.20×10^{-3} , $P = 3.98 \times 10^{-2}$), and tyrosine (beta = -0.03, 95% CI: -5.17 × 10⁻² to -8.46

111 $\times 10^{-3}$, $P = 6.41 \times 10^{-3}$), were observed per one year later onset of puberty.

112 For the 23 metabolites indicating moderate causal consequences of puberty timing,

113 causal effect estimates in sensitivity analyses were broadly consistent with the results

114 of the primary IVW analysis (Table S8-S9). Of note, intercept terms estimated in the

115 MR-Egger regression analysis suggested that some of the results might be biased by

116 horizontal pleiotropy including aspartate, phenylalanine, alpha-aminoadipic acid,

117 lysoPC a C16:0, PC aa C38:0 and PC aa C40:1, which was also supported by

evidence of heterogeneity tested via Cochran's Q statistic in the IVW analysis (Table

119 **S10-S11**).

120 After excluding 7 SNPs associated with birth weight and childhood body mass index

121 (BMI), the secondary IVW analysis confirmed moderate evidence for causal

associations of later puberty timing with higher levels of 16 metabolites out of the

aforementioned 23 metabolites in the primary two-sample MR analysis. It is

noteworthy that 3 additional metabolites, including dodecenoylcarnitine: beta = 0.06,

125 95% CI: 2.75×10^{-3} to 1.10×10^{-2} , $P = 3.94 \times 10^{-2}$; tryptophan: beta = 0.04, 95% CI:

126 5.61×10^{-3} to 8.25×10^{-2} , $P = 2.47 \times 10^{-2}$; and kynurenine: beta = 0.06, 95% CI: 1.57

127 \times 10⁻² to 9.58 \times 10⁻², $P = 6.38 \times 10^{-3}$, appeared to be impacted by puberty timing in

128 the secondary IVW analysis, after controlling for potentially horizontal pleiotropic

129	effects via birth weight or childhood adiposity. On the contrary, 10 out of the 23
130	putative metabolites observed in the primary analysis turned to statistically non-
131	significant in the secondary IVW analysis (Fig 4, Table S12), which included
132	phenylalanine, threonine, asparagine, aspartate, tyrosine, trans-hydroxyproline,
133	lysoPC a C17:0, lysoPC a C18:0, lysoPC a C18:1, and lysoPC a C18:2. Among them,
134	intercept terms estimated in the MR-Egger regression analysis suggested possible
135	horizontal pleiotropy for phenylalanine and heterogeneity for aspartate and lysoPC a
136	C18:1 (Table S13-S14).

137 Mediation analysis

The estimated causal effects of adulthood BMI on 174 metabolites suggested that 138 139 adulthood BMI strongly influenced plasma concentrations of some metabolites through two-step MR analysis, including 35 metabolites reaching nominal 140 significance and 13 reaching statistical significance after the multiple testing 141 Bonferroni correction (Table S15). Further, we found a causal effect of puberty 142 timing (beta = -0.13, 95% CI: -0.17 to -0.09, $P = 8.71 \times 10^{-12}$) on the mediator (i.e., 143 adulthood BMI). By exploiting the "product of coefficients" method, we derived the 144 indirect effects of puberty timing on each plasma metabolite (Table S15). For 145 instance, we found that each year of delayed puberty onset was associated with 0.01 146 SD units increase in serine through the pathway of adulthood adiposity (beta = 0.01, 147 95% CI: 1.04×10^{-3} to 2.44×10^{-2} , P = 0.03), indicating that adulthood adiposity was 148 a putative factor that mediated the causal relationships of puberty timing on certain 149 150 metabolites. To further rule out the influence of horizontal pleiotropy, we removed a total of 13 SNPs highly related to childhood adiposity and birth weight from 151 adulthood BMI and puberty timing genetic instrument sets. A total of 31 metabolites 152

153 reached nominal significance and 8 reached the multiple testing Bonferroni corrected significance level. Moreover, the effect size of puberty timing on adulthood adiposity 154 attenuated from -0.13 kg/m² to -0.09 kg/m² (beta= -0.09, 95% CI: -0.11 to -0.06, P =155 1.81×10^{-8}). Nevertheless, the mediating role of adulthood BMI between puberty 156 timing and adulthood metabolites persisted when the potential pleiotropic effects were 157 adjusted for (Table S17). 158 The MVMR analysis results supported causal evidence for direct causal effects of 159 puberty timing on 10 metabolites (i.e., carnitine, dodecanedioylcarnitine, 160 161 hydroxytetradecenoylcarnitine, tigylcarnitine, lysine, ornithine, cis-hydroxyproline, trans-hydroxyproline, lysoPC a C20:4, and PC aa C40:4) based on nominal 162 significance threshold of P < 0.05. Moreover, among the 10 significant metabolites. 163 the results suggested that carnitine, dodecanedioylcarnitine, tigylcarnitine 164 (acylcarnitines), lysine (amino acids), and lysoPC a C20:4 (lysophosphatidylcholines) 165 166 were directly affected by puberty timing and had the same direction as results in the primary analysis (Fig 5; Table S16). Notably, the effect sizes attenuated to varying 167 degrees, because adulthood BMI was adjusted for in the MVMR analysis. For 168 169 example, the coefficient for dodecanedioylcarnitine attenuated from 0.11 SD units to 0.07 SD units per year later onset of puberty, approximately half of the original 170 estimate. Compared with the results in the primary MR analysis, except for 171 phenylalanine and tyrosine (amino acids) which showed inconsistent directions, the 172 173 remaining 21 metabolites showed the same direction as the primary two-sample MR 174 analysis. Furthermore, the MVMR analysis suggested that the plasma levels of 17 metabolites (i.e., hydroxyhexadecenoylcarnitine, nonaylcarnitine, valerylcarnitine, 175 asparagine, aspartate, methionine, phenylalanine, serine, threonine, tyrosine, sarcosine, 176 trans-hydroxyproline, lysoPC a C16:0, lysoPC a C17:0, lysoPC a C18:0, lysoPC a 177

C18:1, lysoPC a C18:2) were mediated by adulthood BMI rather than directly affected
by puberty timing (Table S16; Table S18).

180 **Replication analysis**

We attempted to replicate the effect estimates for puberty timing on the identified nine 181 metabolites in the UKB. In the two-sample MR analysis, a nominally significant 182 causal relationship was revealed between puberty timing and two amino acids, namely 183 phenylalanine (beta = -0.03, 95% CI: -5.38 \times 10⁻² to -2.45 \times 10⁻³, P = 3.18 \times 10⁻²) and 184 valine (beta = -0.04, 95% CI: -6.54 \times 10⁻² to -3.82 \times 10⁻³, $P = 2.77 \times 10^{-2}$, although 185 none of the nine amino acids reached the strictly adjusted P threshold of 5.56×10^{-3} 186 (0.05/9) (Fig 6; Table S19). Causal effect estimates in the replication analysis of the 187 188 UKB data were consistent with those estimated in the primary two-sample MR analysis except for isoleucine and glutamine. Notably, consistent with the primary 189 MVMR analysis results, in the MVMR analysis using the UKB data, the causal 190 effects attenuated towards null after adjusting for adulthood adiposity, suggesting little 191 direct effects were observed between puberty timing and the nine amino acids (Fig 6; 192 193 Table S20).

194 **Discussion**

Plasma levels of metabolites have been investigated as promising biomarkers for
disease risk stratification and critical molecular targets for developing novel
treatments and interventions for a range of diseases and conditions ¹⁷⁻²⁰. Given that
puberty timing is consistently associated with the risk of developing various chronic
diseases in adulthood ²¹, further causal insights into the relationship between puberty
timing and plasma levels of metabolites will help understand underlying biological

201 mechanisms and identify possible putative target biomarkers for disease treatment or intervention. Here, we systematically and extensively investigated the lifelong 202 impacts of puberty timing on human plasma metabolic profiles, by integrating data on 203 human puberty timing and plasma metabolism in the MR causal inference framework. 204 Genetically predicted puberty timing appeared to have causal effects on 23 plasma 205 metabolites in adulthood. After considering the potential mediating role of adulthood 206 207 adiposity, direct causal effects of puberty timing on 10 adulthood metabolites remained, suggesting the causal effects of puberty timing on certain metabolites in 208 209 adulthood were mediated by adulthood adiposity. Our findings in the primary MR analysis were further supported by the results from the mediation analysis and 210 external replication analysis in the UKB. 211 Among the 23 plasma metabolites identified in the two-sample MR analysis, seven 212 belong to acylcarnitines. In MVMR analysis, 5 of the 10 metabolites affected by 213 214 puberty timing were also confirmed within the subclass of acylcarnitines, including carnitine, tigylcarnitine (short-chain), dodecanedioylcarnitine, 215 hydroxytetradecenoylcarnitine, and octadecenoylcarnitine (medium- and long-chain). 216 217 With the causal effect estimates ranging from 0.05 SD to 0.07 SD per year of delayed puberty onset, our findings suggested that certain acylcarnitine metabolites were 218 directly and independently impacted by puberty timing. Acylcarnitines were a group 219 of compounds formed from carnitine and acyl-CoAs in mitochondria or peroxisomal 220 by carnitine acyltransferases ^{22,23}, which can cross mitochondrial and cell membranes. 221 222 Short-chain acylcarnitines are generated from the degradation of glucose, amino acids, and fatty acids. Medium- and long-chain acylcarnitines are largely produced from 223 fatty acids participating in the transportation of fatty acids for the following fatty acids 224 oxidation ²⁴. It has been well understood that increased plasma levels of acylcarnitine 225

are associated with a higher risk of cardiovascular disease ²⁵⁻²⁷. The underlying 226 mechanism might be the accumulation of acylcarnitine was associated with a 227 disturbed β -oxidation rate and mitochondrial dysfunction ^{28,29}. In addition, previous 228 studies have shown that a shorter reproductive lifespan is associated with an increased 229 risk of cardiovascular disease events ³⁰. Furthermore, in our study, we found a positive 230 causal effect of delayed puberty timing on the accumulation of acylcarnitine. Taking 231 together, our findings may shed new light on the correlation between puberty timing 232 and cardiovascular diseases. However, whether puberty timing affects cardiovascular 233 234 diseases through the acylcarnitine metabolism pathway has not been illuminated, thus more studies are warranted. 235 Of note, we found 8 amino acids in adulthood were significantly impacted by puberty 236 timing in the primary MR analysis, among which inverse causal effects of puberty 237 timing on the concentrations of tyrosine and phenylalanine were externally validated 238 239 using data from the UKB. After accounting for adulthood adiposity in the MVMR analysis, the direct causal effects of puberty timing on these 8 amino acids attenuated 240 to null in both the primary and replication MVMR analysis. It suggests a mediating 241 242 role of adulthood adiposity in the causal pathway from puberty timing to the

aforementioned amino acids. Our findings were partly consistent with the findings

from a previous study ¹⁶, where an inverse association between age at menarche and

245 phenylalanine measured at 18 years old was revealed in the conventional

observational analysis among the females in the Avon Longitudinal Study of Parents

and Children (ALSPAC), but a causal association was failed to be established in the

one-sample MR analysis using the same ALSPAC cohort data.

In our two-step MR analysis, we found that adulthood BMI influenced the levels of 35 249 metabolites, and adulthood BMI itself was also influenced by puberty timing. After 250 adjusting for adulthood BMI through MVMR analysis, the number of metabolites 251 influenced by puberty timing decreased from 23 to 10. Our findings suggested that 252 adulthood BMI may serve as a mediator between puberty timing and plasma 253 metabolites. The reason lies in the fact that early-maturing individuals may face a 254 255 higher risk of obesity and exhibit a higher likelihood of metabolic abnormalities in adulthood ³¹. Obesity can also significantly increase the risk of developing metabolic 256 257 disorders by affecting energy metabolism and altering pathways ³², which could be the reason for changes in acylcarnitine and amino acid metabolism. 258 The strengths of this study were as follows. First, the data we used were curated from 259 the latest and largest GWAS in European ancestry. Second, the MR mediation analysis 260 makes it possible to infer the direct and indirect effects of genetically predicted 261 262 puberty timing on adulthood plasma levels of metabolites. In the two-step MR analysis, we used adulthood BMI as a mediator to investigate the indirect effects of 263 puberty timing on metabolites. As for MVMR analysis, we included both adulthood 264 265 BMI and puberty timing as exposures to explore the direct effect of puberty timing on metabolites. Third, to minimize the risk of bias due to horizontal pleiotropy, we 266 excluded SNPs that had genome-wide significant associations with birth weight or 267 childhood obesity. Finally, external replication analysis using data from the UKB 268 supported our primary analysis results, suggesting the robustness of our findings. 269 270 Limitations were also noted. First, our study results were primarily based on GWAS

conducted in individuals of European descent. Consequently, it should be cautious
when generalizing the results to non-European populations. Second, despite extensive

analyses were performed to minimize the risk of bias due to horizontal pleiotropy, it 273 cannot be fully ruled out, thus the results should be interpreted with caution. Third, 274 the puberty timing GWAS were conducted in females exclusively, while the 275 metabolites GWAS included female and male individuals. As there may be sex-276 specific effects on the levels of metabolites ³³, this could potentially impact our causal 277 effect estimates. Thus, future studies taking into account the sex-specific effects with 278 regard to the relationship between puberty timing and human plasma metabolism are 279 warranted. 280

In summary, we explored the causal relationship of puberty timing with human

282 plasma metabolite levels using publicly available GWAS summary data. We found a

causal effect of puberty timing on 23 plasma metabolites through two-sample MR

analysis, and most of the effects were mediated by adulthood adiposity. The findings

285 provide novel insights into the causal inferences of puberty timing on human

286 metabolism. Additionally, the role of adulthood adiposity in mediating the causal

relationship between puberty timing and plasma metabolites is identified.

288 Material and Methods

289 Data sources

290 The information on all GWAS data used in the analyses is shown in **Table S21**.

291 Summary statistics on age at menarche (AAM) (measured in years) were obtained

- from the largest meta-analysis of GWASs, including 329,345 women of European
- ancestry from 42 cohort studies ³⁴. A total of 389 SNPs reaching genome-wide
- significance ($P < 5 \times 10^{-8}$) were identified. There exists a genetic correlation ($r_g=0.74$)
- between the AAM of females and the age at voice breaking of males, which suggests

296 that many genetic variants have comparable effects on puberty timing in both males and females. Consequently, there was credibility that genetic variants of AAM can 297 provide confident insights into puberty timing in males as well³⁵. Thus, in our study, 298 these genetic variants were considered instrumental variables for puberty timing. We 299 also refer to AAM as puberty timing in the present study. 300 301 A total of 174 plasma metabolites in seven biochemical categories (i.e., amino acids, biogenic amines, acylcarnitines, phosphatidylcholines, lysophosphatidylcholines, 302 sphingomyelins, and hexoses), from the largest GWAS of human plasma metabolites, 303 304 were used as the outcomes in this study ³⁶. Summary statistics on all metabolites measured by high-throughput platforms were obtained from the cross-platform meta-305 analysis GWAS of blood metabolites, which included several cohorts with sample 306 sizes for each metabolite ranging from 8,569 to 86,507 individuals of European 307 ancestry. The GWASs were undertaken in cohorts of Fenland study (N = 9.363), 308 EPIC-Norfolk (European Prospective Investigation into Cancer-Norfolk) (N = 5,841), 309 and INTERVAL study (Metabolon Discovery HD4 platform, N = 8,455 and ¹H 310 nuclear magnetic resonance (NMR), Nightingale, N = 40,905). The results were 311 312 further meta-analyzed with two published studies conducted by Kettunen et al. (N =24,925) and Shin et al. $(N = 7,824)^{37,38}$. 313

The adulthood adiposity GWAS conducted by the Genetic Investigation of

315 Anthropomorphic Traits (GIANT) consortium included 315,347 adults of European

ancestry, combining data from the Research Program on Genes, Environment, and

317 Health (RPGEH), Genetic Epidemiology Research on Aging (GERA) cohort and a

318 meta-analysis of GWASs conducted by Locke et al. ^{39,40}. A total of 147 genome-wide

319 significant variants associated with adulthood BMI were selected as genetic

320 instruments in the MR mediation analysis.

321	Since birth weight and childhood adiposity have been reported to be associated with
322	puberty timing and plasma metabolite level changes in previous studies ⁴¹⁻⁴³ , we
323	excluded SNPs, which were genetically significantly associated with these two traits,
324	from the genetic instruments for puberty timing to minimize the potential risk of bias
325	due to horizontal pleiotropy. Full summary data on birth weight and childhood BMI
326	were obtained from the Early Growth Genetics (EGG) Consortium ^{43,44} . In the birth
327	weight GWAS, Warrington et al. conducted a meta-analysis of the fetal genetic effects
328	in up to 297,356 Europeans with their own birth weight and 210,248 Europeans with
329	offspring birth weight ⁴³ . Bradfield et al. performed a trans-ancestral GWAS meta-
330	analysis of childhood BMI from 30 studies, but only data on Europeans were used in
331	the analyses ⁴⁴ .

332 We then attempted to replicate the findings of our study by using data from

333 independent GWASs. Data on puberty timing were obtained from a GWAS conducted

on up to 182,416 females of European descent from 58 studies ⁴⁵. Summary statistics

on adulthood BMI were obtained from a meta-analysis of 322,154 European

ancestries from the GIANT consortium ⁴⁰. Furthermore, we obtained summary

337 statistics from a GWAS of metabolites measured in the UKB, which were conducted

- on over 114,000 individuals of European ancestry ⁴⁶.
- 339 Genetic instruments selection

340 To ensure statistical independence between genetic instruments, we performed a

stringent linkage disequilibrium (LD) clumping (window = 10 MB and $r^2 < 0.001$ in

342	PLINK 1.9) using the European ancestry data set of the 1000 Genomes Project as a
343	reference panel and selected all the bi-allelic SNPs with minor allele frequency
344	(MAF) > 0.01 using the clump data function in the TwoSample MR R package ⁴⁷ .
345	After LD clumping, 208 and 147 SNPs were selected as genetic instruments for
346	puberty timing and adulthood BMI, respectively. Of note, when a SNP instrumenting
347	for the exposure of interest was not available in the outcome summary data, a proxy
348	variant in high-LD with the SNP (window = 1MB and $r^2 > 0.80$ in European ancestry)
349	was looked up using the online platform LDlink (https://ldlink.nci.nih.gov/). SNPs
350	would be removed from the sets of genetic instruments if no available proxies can be
351	identified. As no qualified alternative proxy variants were found in each step, the
352	analyses did not use any proxy SNPs. Detailed information on IVs for puberty timing
353	and adulthood BMI is presented in Table S1-S6.

354 Statistical analysis

355 **Two-sample MR analysis**

As shown in **Fig 1**, a two-sample MR analysis was used as the primary analysis 356 approach to examine the causal effects of genetically predicted puberty timing on 174 357 human plasma metabolites. The IVW method, which assumes no correlations or 358 interactions between genetic instruments and generates average causal effect estimates 359 across multiple instruments, was used in the primary MR analysis ⁴⁸. The causal effect 360 estimates were interpreted as standardized mean differences in concentrations of 361 metabolites per year delayed onset of puberty. Heterogeneity between causal effect 362 estimates for each SNP was examined by calculating Cochran's Q statistic, which 363 indicated potentially horizontal pleiotropy. 364

365 MR mediation analysis

366	To investigate the extent, to which adulthood adiposity might mediate the causal
367	relationship between puberty timing and metabolite levels, we performed an MR
368	mediation analysis (Fig 1-2). The indirect causal effects of puberty timing on plasma
369	metabolite levels were estimated using the two-step MR method ⁴⁹ . In the first step,
370	we tested the causal effects of adulthood BMI on all plasma metabolite levels. In the
371	second step, we tested the causal effect of puberty timing on adulthood BMI. Then we
372	used the "product of coefficients" approach 50 to calculate the indirect causal effects of
373	puberty timing on each blood metabolite via adulthood BMI. The standard error of
374	each indirect causal effect was estimated by using the "multivariate delta method" ⁵¹ .
375	Compared with conventional univariable two-sample MR, which estimates the total
376	effect of one exposure on the outcome, MVMR includes multiple risk factors as
377	exposures to estimate the direct causal effect on the outcome after adjusting for other
378	risk factors ⁵² . We accomplished MVMR analysis to assess the direct causal effects of
379	both puberty timing and adulthood BMI on 174 plasma metabolites. Since only
380	participants involved in the ReproGen consortium were available in the full summary
381	statistics of puberty timing GWAS ³⁴ , a total of 207 IVs for puberty timing used in the
382	MVMR were directly selected from the summary data following the same LD
383	clumping strategy.

384 Sensitivity analysis

385 To assess the robustness of our results in the two-sample MR analysis, we also 386 performed four other sensitivity analyses. MR-Egger regression provides an unbiased 387 estimate of the causal effect even if all SNPs used as instrumental variables are invalid

388	⁵³ . The weighted median model requires that at least 50% of the SNPs were valid
389	genetic instruments to provide unbiased estimates of causal effects in MR analyses ⁵⁴ .
390	The weighted mode method provides consistent causal effect estimates even if the
391	majority of SNPs were invalid ⁵⁵ . The Mendelian Randomization Pleiotropy RESidual
392	Sum and Outlier (MR-PRESSO) method detects outlying genetic variants that might
393	lead to horizontal pleiotropy and further provides causal effect estimates after
394	removing outliers ⁵⁶ . Horizontal pleiotropy was tested via the intercept terms in the
395	MR-Egger regression analysis.
396	As birth weight and childhood obesity were investigated as common causes of
397	puberty timing and some of the adulthood metabolite levels ⁵⁷ , to minimize the risk of
398	violating one of the MR core assumptions (i.e., exclusion restriction assumption) ⁵⁸ ,
399	we excluded SNPs that were genetically significantly associated with birth weight or
400	childhood BMI ($P < 5 \times 10^{-8}$) from genetic instruments. Based on this, a secondary
401	IVW analysis was performed with the reduced genetic instrument sets.
402	Replication analysis in the UK Biobank
403	The UKB, a population-based cohort, has recruited approximately 500,000
404	individuals aged 40 to 69 years across the UK. By utilizing the targeted high-
405	throughput nuclear magnetic resonance (NMR) metabolomics platform (Nightingale
406	Health Ltd; biomarker quantification version 2020), 249 metabolic measures (i.e., 165
407	metabolic measures and 84 derived ratios) were quantified simultaneously ⁴⁶ .
408	However, given that only nine of the metabolites (i.e., alanine, glutamine, glycine,
409	histidine, isoleucine, leucine, phenylalanine, tyrosine, and valine) measured in the

- 410 UKB were identified to coincide with the metabolites included in the primary analysis,
- 411 we merely estimated the relationship between puberty timing and the nine amino

412 acids to inspect the robustness of our primary analysis results. Firstly, we conducted a two-sample MR analysis to investigate the total effect of puberty timing on each 413 amino acid. Subsequently, we also performed MVMR analysis to obtain the direct 414 impact of puberty timing on amino acids after adjusting for adulthood adiposity. Of 68 415 SNPs identified as associated with puberty timing, 60 were eventually used in two-416 sample MR, and the 8 SNPs were removed due to being palindromic with 417 418 intermediate allele frequencies. A total of 55 SNPs were employed in MVMR analysis after LD clumping. 419

420 Multiple testing correction

421 Given that a large number of tests were performed, a conservative Bonferroni

422 multiple-test correction was applied. The *P* value threshold for statistical significance

423 becomes $P < 4.90 \times 10^{-4} (0.05/102)$ after correcting for 102 tests corresponding to the

424 number of principal components explained 95% of the variance of the 174 metabolites

425 in the GWAS by Lotta et al. ⁵⁹, which indicated strong causal evidence for our results.

426 Meanwhile, the conventional *P* value threshold of 0.05 was also reported to avoid

427 ignoring potentially crucial findings after constructing a "suggestive significance

428 threshold" ^{60,61}, which offered moderate causal evidence.

429 All statistical analyses were performed using R version 4.1.2, in which the

430 TwoSampleMR (version 0.5.6) and MRPRESSO (version 1.0) packages were used

^{47,56}. The ggpolt2 and circlize R packages were used to visualize statistical analysis
results ^{62,63}.

433 **Data availability**

434	The genetic instruments	for pul	berty tim	ing were	obtained	from th	e corresponding
-----	-------------------------	---------	-----------	----------	----------	---------	-----------------

- 435 literature at <u>https://reprogen.org/data_download.html</u>. Data on plasma metabolites
- 436 GWAS can be found at <u>www.omicscience.org</u>. Full summary data on adulthood BMI
- 437 were obtained from the MRC Integrative Epidemiology Unit OpenGWAS project
- 438 (<u>https://gwas.mrcieu.ac.uk/</u>). Full summary data on birth weight and childhood BMI
- 439 were obtained from the Early Growth Genetics Consortium (egg-consortium.org). The
- 440 replication analyses were conducted using data from the UKB
- 441 (https://www.ukbiobank.ac.uk/) and the summary level data were obtained at
- 442 <u>https://gwas.mrcieu.ac.uk/.</u>

443 Code availability

444 Scripts are available on GitHub at <u>https://github.com/ZengjunLi/Puberty_metabolites</u>.

445 **References**

- Toppari, J. & Juul, A. Trends in puberty timing in humans and environmental modifiers. *Molecular and Cellular Endocrinology* 324, 39-44 (2010).
- 448 2. Day, F.R., Perry, J.R.B. & Ong, K.K. Genetic Regulation of Puberty Timing in Humans.
 449 *Neuroendocrinology* 102, 247-255 (2015).
- 450 3. Pinyerd, B. & Zipf, W.B. Puberty—Timing Is Everything! *Journal of Pediatric Nursing* 20,
 451 75-82 (2005).
- 4. Li, W. *et al.* Association between Obesity and Puberty Timing: A Systematic Review and
 Meta-Analysis. in *International Journal of Environmental Research and Public Health* Vol. 14
 454 (2017).
- 455 5. Prentice, P. & Viner, R.M. Pubertal timing and adult obesity and cardiometabolic risk in
 456 women and men: a systematic review and meta-analysis. *International Journal of Obesity* 37,
 457 1036-1043 (2013).
- 458 6. Cheng, T.S., Day, F.R., Lakshman, R. & Ong, K.K. Association of puberty timing with type 2

- 459 diabetes: a systematic review and meta-analysis. PLoS medicine 17, e1003017 (2020).
- 460 7. Hulanicka, B., Lipowicz, A., Kozieł, S. & Kowalisko, A. Relationship between early puberty
- 461 and the risk of hypertension/overweight at age 50: Evidence for a modified Barker hypothesis 462 among Polish youth. Economics & Human Biology 5, 48-60 (2007).
- 463 8. Biro, F.M., Huang, B., Wasserman, H., Gordon, C.M. & Pinney, S.M. Pubertal Growth, IGF-1,
- 464 and Windows of Susceptibility: Puberty and Future Breast Cancer Risk. Journal of Adolescent 465 Health 68, 517-522 (2021).
- 466 9. Galvao, T.F. et al. Pubertal timing in girls and depression: A systematic review. Journal of 467 Affective Disorders 155, 13-19 (2014).
- 468 10. Park, J., Shin, Y., Kim, T.H., Kim, D.-H. & Lee, A. Plasma metabolites as possible biomarkers 469 for diagnosis of breast cancer. PLoS One 14, e0225129 (2019).
- 470 11. Zhao, Y., Lv, H., Qiu, S., Gao, L. & Ai, H. Plasma metabolic profiling and novel metabolite 471 biomarkers for diagnosing prostate cancer. RSC advances 7, 30060-30069 (2017).
- 472 Heys, M. et al. Age of Menarche and the Metabolic Syndrome in China. Epidemiology 12. 473 18(2007).
- 474 13. Feng, Y. et al. Effects of age at menarche, reproductive years, and menopause on metabolic 475 risk factors for cardiovascular diseases. Atherosclerosis 196, 590-7 (2008).
- 476 14. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology 477 contribute to understanding environmental determinants of disease?*. International Journal of 478 *Epidemiology* **32**, 1-22 (2003).
- 479 Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N. & Davey Smith, G. Mendelian 15. 480 randomization: Using genes as instruments for making causal inferences in epidemiology. 481 Statistics in Medicine 27, 1133-1163 (2008).
- 482 16. Bell, J. et al. Influence of puberty timing on adiposity and cardiometabolic traits: A Mendelian 483 randomisation study. PLOS Medicine 15, e1002641 (2018).
- 484 17. Yuan, B. et al. A plasma metabolite panel as biomarkers for early primary breast cancer 485 detection. International Journal of Cancer 144, 2833-2842 (2019).
- 486 18. Knific, T. et al. Models including plasma levels of sphingomyelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer. The Journal of Steroid 487 488 Biochemistry and Molecular Biology 178, 312-321 (2018).

- 489 19. Li, S., Gao, D. & Jiang, Y. Function, Detection and Alteration of Acylcarnitine Metabolism in 490 Hepatocellular Carcinoma. Metabolites 9(2019).
- 491 20. Takaya, H. et al. Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular 492 carcinoma in non-steatohepatitis patients. World J Gastrointest Oncol 11, 887-897 (2019).
- 493 21. Day, F.R., Elks, C.E., Murray, A., Ong, K.K. & Perry, J.R. Puberty timing associated with
- 494 diabetes, cardiovascular disease and also diverse health outcomes in men and women: the UK 495 Biobank study. Sci Rep 5, 11208 (2015).
- 496 22. Kerner, J. & Hoppel, C. Fatty acid import into mitochondria. Biochimica et Biophysica Acta 497 (BBA) - Molecular and Cell Biology of Lipids 1486, 1-17 (2000).
- 498 23. Violante, S. et al. Peroxisomes contribute to the acylcarnitine production when the carnitine 499 shuttle is deficient. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of 500 Lipids 1831, 1467-1474 (2013).
- 501 24. Meierhofer, D. Acylcarnitine profiling by low-resolution LC-MS. PLoS One 14, e0221342 502 (2019).
- 503 25. Guasch-Ferré, M. et al. Plasma acylcarnitines and risk of cardiovascular disease: effect of 504 Mediterranean diet interventions. Am J Clin Nutr 103, 1408-16 (2016).
- 505 26. Kaul, P. et al. Incidence of heart failure and mortality after acute coronary syndromes. Am 506 Heart J 165, 379-85.e2 (2013).
- 507 27. Kalim, S. et al. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident 508 dialysis patients. J Am Heart Assoc 2, e000542 (2013).
- 509 28. Nicholas, D.A. et al. Fatty Acid Metabolites Combine with Reduced B Oxidation to Activate
- 510 Th17 Inflammation in Human Type 2 Diabetes. Cell Metab 30, 447-461.e5 (2019).
- 511 29. Jarrell, Z.R. et al. Plasma acylcarnitine levels increase with healthy aging. Aging (Albany NY) 512 12, 13555-13570 (2020).
- 513 30. Mishra, S.R., Chung, H.F., Waller, M. & Mishra, G.D. Duration of estrogen exposure during 514 reproductive years, age at menarche and age at menopause, and risk of cardiovascular disease 515 events, all-cause and cardiovascular mortality: a systematic review and meta-analysis. BJOG: 516 An International Journal of Obstetrics & Gynaecology 128, 809-821 (2021).
- 517 31. Richardson, T.G., Sanderson, E., Elsworth, B., Tilling, K. & Davey Smith, G. Use of genetic 518 variation to separate the effects of early and later life adiposity on disease risk: mendelian

- 519 randomisation study. Bmj 369, m1203 (2020).
- 520 32. Zhou, Y. et al. Obesity and diabetes related plasma amino acid alterations. Clinical 521 Biochemistry 46, 1447-1452 (2013).
- 522 33. Verri Hernandes, V. et al. Age, Sex, Body Mass Index, Diet and Menopause Related 523 Metabolites in a Large Homogeneous Alpine Cohort. Metabolites 12(2022).
- 524 34. Day, F.R. et al. Genomic analyses identify hundreds of variants associated with age at 525 menarche and support a role for puberty timing in cancer risk. Nat Genet 49, 834-841 (2017).
- 526 35. Day, F.R. et al. Shared genetic aetiology of puberty timing between sexes and with health-527 related outcomes. Nature Communications 6, 8842 (2015).
- 528 36. Lotta, L.A. et al. A cross-platform approach identifies genetic regulators of human metabolism 529 and health. Nat Genet 53, 54-64 (2021).
- 530 37. Kettunen, J. et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals 531 novel systemic effects of LPA. Nat Commun 7, 11122 (2016).
- 532 38. Shin, S.Y. et al. An atlas of genetic influences on human blood metabolites. Nat Genet 46, 533 543-550 (2014).
- 534 39. Hoffmann, T.J. et al. A Large Multiethnic Genome-Wide Association Study of Adult Body 535 Mass Index Identifies Novel Loci. Genetics 210, 499-515 (2018).
- 536 40. Locke, A.E. et al. Genetic studies of body mass index yield new insights for obesity biology. 537 Nature 518, 197-206 (2015).
- 538 41. Wang, Y., Dinse, G.E. & Rogan, W.J. Birth weight, early weight gain and pubertal maturation: 539 a longitudinal study. Pediatr Obes 7, 101-9 (2012).
- 540 Bull, C.J. et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization 42. 541 study. BMC Med 18, 396 (2020).
- 542 43. Warrington, N.M. et al. Maternal and fetal genetic effects on birth weight and their relevance 543 to cardio-metabolic risk factors. Nat Genet 51, 804-814 (2019).
- 544 44. Bradfield, J.P. et al. A trans-ancestral meta-analysis of genome-wide association studies 545 reveals loci associated with childhood obesity. Hum Mol Genet 28, 3327-3338 (2019).
- 546 45. Perry, J.R. et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature 514, 92-97 (2014). 547
- 548 46. Borges, M.C. et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases

- 549 risk: analysis using Mendelian randomization and fatty acid genetic association data from over 550 114,000 UK Biobank participants. BMC Med 20, 210 (2022). 551 47. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the 552 human phenome. Elife 7(2018). 553 48. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis with 554 multiple genetic variants using summarized data. Genet Epidemiol 37, 658-65 (2013). 555 49. Relton, C.L. & Davey Smith, G. Two-step epigenetic Mendelian randomization: a strategy for 556 establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol 41, 557 161-76 (2012). 558 50. VanderWeele, T.J. Mediation Analysis: A Practitioner's Guide. Annu Rev Public Health 37, 17-559 32 (2016). 560 51. MacKinnon, D.P., Fairchild, A.J. & Fritz, M.S. Mediation analysis. Annu Rev Psychol 58, 593-561 614 (2007). 562 52. Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of 563 multivariable Mendelian randomization in the single-sample and two-sample summary data 564 settings. Int J Epidemiol 48, 713-727 (2019).
 - 565 53. Bowden, J. et al. Assessing the suitability of summary data for two-sample Mendelian 566 randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol 567 45, 1961-1974 (2016).
 - Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent Estimation in 568 54. 569 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median 570 Estimator. Genet Epidemiol 40, 304-14 (2016).
 - 571 55. Hartwig, F.P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian 572 randomization via the zero modal pleiotropy assumption. International Journal of 573 Epidemiology 46, 1985-1998 (2017).
 - 574 56. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy 575 in causal relationships inferred from Mendelian randomization between complex traits and 576 diseases. Nature Genetics 50, 693-698 (2018).
 - 577 57. Bell, J.A. et al. Influence of puberty timing on adiposity and cardiometabolic traits: A 578 Mendelian randomisation study. PLoS Med 15, e1002641 (2018).

579	58.	Boef, A.G.C., Dekkers, O.M. & le Cessie, S. Mendelian randomization studies: a review of the
580		approaches used and the quality of reporting. International Journal of Epidemiology 44, 496-
581		511 (2015).
582	59.	Lotta, L.A. et al. A cross-platform approach identifies genetic regulators of human metabolism
583		and health. Nat Genet 53, 54-64 (2021).
584	60.	Sterne, J.A.C. & Smith, G.D. Sifting the evidence-what's wrong with significance tests?
585		<i>Physical Therapy</i> 81 , 1464-1469 (2001).
586	61.	Amrhein, V., Greenland, S. & McShane, B. Scientists rise up against statistical significance.
587		(Nature Publishing Group, 2019).
588	62.	Wickham, H. Ggplot2: Elegant Graphics for Data Analysis, (ggplot2: Elegant Graphics for
589		Data Analysis, 2009).
590	63.	Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular
591		visualization in R. Bioinformatics 30, 2811-2 (2014).

593 Acknowledgements

- 594 This study was supported by grants from the National Natural Science Foundation of
- 595 China (82373588, 82125032, 81930095 and 81761128035), Xinhua Hospital,
- 596 Shanghai Jiao Tong University School of Medicine, Shanghai, China (2021YJRC02),
- 597 Innovative research team of high-level local universities in Shanghai (SHSMU-
- 598 ZDCX20211100), the Science and Technology Commission of Shanghai Municipality
- 599 (19410713500 and 2018SHZDZX01), the Shanghai Municipal Commission of Health
- and Family Planning (GWV-10.1-XK07, 2020CXJQ01, 2018YJRC03) and Sichuan
- 601 Science and Technology Program (2021JDR0189). The funders of the study had no
- role in the study design, data collection, data analysis, or data interpretation; writing
- or reviewing of the manuscript; and decision to submit the manuscript for publication.

604 Author information

605 Authors and Affiliations

- 1. Department of Epidemiology and Biostatistics, West China School of Public Health
- and West China Fourth Hospital, Sichuan University, 610041, China.
- 608 Zengjun Li & Cairong Zhu^{*}
- 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol,United Kingdom.
- 611 Si Fang
- 612 3. Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), University
 613 of Bristol, Bristol, United Kingdom.

614 Si Fang

- 4. Ministry of Education and Shanghai Key Laboratory of Children's Environmental
- 616 Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine,
- 617 Shanghai, 200092, China
- 618 Dong Liu, Fei Li^{*} & Jian Zhao^{*}
- 5. Department of Developmental and Behavioral Pediatric & Child Primary Care,
- 620 Brain and Behavioral Research Unit of Shanghai Institute for Pediatric Research,
- 621 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
- 622 China
- 623 Fei Li*
- 6. Department of Maternal and Child Health, School of Public Health, Shanghai Jiao
 Tong University, 200092, China.
- 626 Fei Li^{*} & Jian Zhao^{*}

627 Contributions

- 628 Cairong Zhu, Fei Li, and Jian Zhao initially conceived the study design. Zengjun Li
- and Si Fang carried out statistical analyses, and Zengjun Li wrote the first draft of the
- 630 manuscript with input from Cairong Zhu, Fei Li, and Jian Zhao. Zengjun Li and Dong
- 631 Liu plotted the figures. All authors contributed to the interpretation of the results and
- 632 critical revision of the manuscript.
- 633 Corresponding author

634 Correspondence to Jian Zhao, Cairong Zhu, and Fei Li.

635

636 Ethical approval

- 637 This study used publicly available GWAS summary data and was not subject to
- 638 institutional review board approval.

639 **Competing interests**

640 The authors declare no competing interests.

641 Supplementary information

642 Table S1-S21.



645 plasma metabolites. The primary analysis was conducted utilizing a two-sample MR 646

647	(Mendelian randomization) approach to investigate the total effect of puberty timing
648	on plasma metabolites. In addition, we employed the two-step MR and MVMR
649	(multivariable Mendelian randomization) approach, taking the mediating effect of
650	adulthood BMI (body mass index) into account to infer the "direct" and "indirect"
651	effects. The IVW (inverse-variance weighted) approach was used as the primary
652	analysis, while MR-Egger, weighted median, weighted mode, and MR-PRESSO
653	(Mendelian randomization pleiotropy residual sum and outlier) were used as
654	sensitivity analyses. Subsequently, we excluded SNPs (single nucleotide
655	polymorphisms) that were genetically associated with birth weight and/or childhood
656	BMI from genetic instruments to minimize the risk of bias due to horizontal
657	pleiotropy. We further used metabolomic data obtained from the UK Biobank to
658	perform a replication analysis, aiming to validate the causal effect estimated.



660

Fig 2. The directed acyclic graphs of the Mendelian randomization study. The figures 661 depict directed acyclic graphs for univariable Mendelian randomization (MR) and mediation 662 MR analysis in panel A and panel B respectively. The dashed lines represent potential 663 horizontal pleiotropy or direct causal effects between variables, which would violate the MR 664 assumption. MR approach is based on three assumptions: (1) the IVs (instrument variables) 665 are strongly associated with the exposure (e.g., puberty timing); (2) the genetic IVs are not 666 associated with any confounders (e.g., birth weight and childhood BMI (body mass index)); 667 (3) the genetic IVs should influence the outcome (e.g., a metabolite) through the exposure 668 independently instead of through other pathways. The primary analysis was performed, 669 670 wherein SNPs that exhibited genetic associations with puberty timing were selected as IVs. To minimize the risk of bias due to horizontal pleiotropy, a secondary analysis was conducted 671 wherein SNPs that exhibited genetic associations with birth weight and/or childhood BMI 672

were excluded. 673



Fig 3. Circos plot depicting the causal effect estimates of puberty timing on all 174 676 plasma metabolites. The legend located at the lower section of the figure provides a visual 677 representation of distinct subclasses of plasma metabolites. The presence of metabolites 678 highlighted with the color blue indicates a positive causal effect of puberty timing on the 679 concentration of plasma metabolites. Specifically, each year later in puberty timing is 680 associated with higher levels of metabolites. In contrast, the identification of metabolites 681 682 highlighted with the color red suggests a negative causal effect of puberty timing on the concentration of plasma metabolites, that is each year later in puberty timing is associated 683 684 with lower levels of metabolites. The presence of metabolites that had been designated as black indicates that there is insufficient evidence to establish a causal relationship. The 685

- evidence indicates a causal effect of puberty timing on 23 plasma metabolites. Error bars
- represent 95% confidence intervals. All statistical tests were two-sided.





metabolites. The legend located on the right side of the forest plot indicates different analysis 690

- approaches. Plasma metabolites reaching nominal significance (P < 0.05) were shown 691
- according to the results of IVW (inverse-variance weighted). The results presented on the left 692

693 side of the plot were analyzed using the IVW approach. The colors represent green, using the IVW method to estimate the effect size of puberty timing on plasma metabolites; blue; using 694 the IVW method, but excluding 7 genetic instruments genetically related to birth weight 695 696 and/or childhood BMI (body mass index). The results presented on the right were derived from four distinct sensitivity analyses. The sensitivity analysis findings indicate that the 697 results of the primary analysis are largely robust. Error bars represent 95% confidence 698 699 intervals. All statistical tests were two-sided. The metabolites were divided according to different subclasses. AA amino acids; AC acylcarnitines; BA biogenic amines; LPC 700

701 lysophosphatidylcholines.







Fig 5. Forest plots comparing the effect estimates of puberty timing and adulthood BMI 703 704 on plasma metabolites in MVMR analyses. The legend located on the right side of the forest indicates the distinct analysis. Plasma metabolites reaching nominal significance ($P \le P$ 705 0.05) in puberty timing were shown according to the results of the MVMR (multivariable 706 Mendelian randomization) approach. The colors represent blue, using the MVMR method to 707 estimate the effect size of puberty timing or adulthood BMI on plasma metabolites; purple; 708 709 using the MVMR method, but excluding 8 genetic instruments associated with birth weight and/or childhood BMI (body mass index). The results on the left show the effect size of 710 puberty timing on each plasma metabolite, whereas the results on the right present the effect 711 size of adulthood BMI on each plasma metabolite. Error bars represent 95% confidence 712 intervals. All statistical tests were two-sided. The metabolites were also divided according to 713 different subclasses. AA amino acids; AC acylcarnitines; BA biogenic amines; LPC 714 lysophosphatidylcholines; PC phosphatidylcholines. 715



Fig 6. Forest plots comparing the effect estimates of puberty timing on nine amino acids 718 719 in replication analyses. The legend located on the right side of the forest plot indicates different analysis methods. The results of two-sample MR (Mendelian randomization) and 720 MVMR (multivariable Mendelian randomization) represented the total (blue) and direct 721 impact (orange) of puberty timing on plasma metabolites, respectively. To inspect the 722 robustness of our two-sample MR and MVMR analysis results (purple and green), we 723 724 estimated the causal relationship of puberty timing on nine identified amino acids using data from the UKB (UK Biobank). Our findings in the primary MR analysis were further 725 supported by the findings from external replication analysis in the UKB. Error bars represent 726 95% confidence intervals. All statistical tests were two-sided. 727